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A B S T R A C T
Albumin nanoparticles are considered to be an effective way to load water-insoluble anti-
cancer drugs and target tumors via the gp60-mediated pathway. Herein, we fabricated an
albumin nanoparticle formulation for co-loading paclitaxel (PTX) and curcumin (CCM), both
of which have prominent anticancer efficacy, via nanoparticle albumin-bound (NabTM) tech-
nology using high-pressure homogenization.The PTX/CCM co-bound albumin nanoparticles
(PTX/CCMAlb-NPs) had a slightly greater particle size of ~250 nm than that of plain PTX Alb-
NPs and CCM Alb-NPs (~234 and ~134 nm, respectively), with spherical surface morphology
and stable size maintenance. However, the zeta potential of PTX/CCM Alb-NPs (ca. −30 mV)
was not significantly different from that of PTX or CCM Alb-NPs. The loaded PTX and CCM
were released gradually from the PTX/CCM Alb-NPs over ~24 h (97.7 ± 1.7% and 76.2 ± 0.5%,
respectively). Furthermore, PTX/CCMAlb-NPs appeared to be efficiently internalized into Mia
Paca-2 cells and exhibited a 71% increased IC50 versus PTX Alb-NPs in terms of cytotoxicity
to Mia Paca-2 cells. These results suggest that PTX/CCM Alb-NPs are a new potential anti-
cancer agent for combination therapy.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Albumin is a large molecular weight (~66.5 kDa) natural en-
dogenous protein present in humans.This protein has gained
great interest as a useful biomaterial because it is very safe
and well tolerated [1,2]. Albumin is biocompatible and biode-
gradable and possesses many chemical groups for
functionalizing drug or ligand attachments such as amines, car-
boxylates, and thiols on its surface [3–5]. Albumin is used for
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two major purposes in pharmaceutical field; albumin extends
the very short circulating half-lives of peptides or proteins and
acts as a carrier protein for nano-delivery systems [1]. These
advantages have expanded the utility of albumin in pharma-
ceutical and medical applications.
Curcumin [(E,E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)-1,6-
heptadiene-3,5-dione] (CCM) is a pharmacologically active
polyphenolic compound present in Curcuma longa (turmeric)
and has been traditionally used as a natural spice and food-
stuff [6,7]. CCM has been considered an attractive antitumor,
chemopreventive, and anti-inflammatory agent [8–10]. Particu-
larly, CCM inhibits nuclear factor-kappa beta, which is involved
in the pathogenesis of several malignancies [11], and also in-
hibits the production of many cytokines, such as tumor necrosis
factor (TNF)-α and interleukin-1β [12]. Moreover, CCM is toxic
to many cancer cell lines, such as breast, pancreatic, colonic,
hepatic, and gastric cancer cells [13]. Accordingly, CCM shows
increasing potential as an anti-cancer agent.
Paclitaxel (PTX) is one of the most widely used anti-
mitotic chemotherapeutic agents for treating many types of
cancers, such as ovarian, breast, lung, pancreatic, and other
cancers, by preventing microtubule depolymerization and ar-
resting mitosis at the G2/M stages of the cell cycle [14,15]. It
is also capable of inducing apoptosis-mediated cell death [16].
Three PTX formulations are commercially available, such as
Taxol® (cremophor formulated) [17], AbraxaneTM (nanoparticle
albumin bound: NabTM technology) [9], and Genexol®-PM (PEG-
PLA micelles) [18].
Cancers are a prominent cause of death [19]. Most of all,
the high death rates from cancers involve multidrug resis-
tance, which is primarily caused by mutations in tumor cells
or expression of alternative compensatory signaling path-
ways [20]. Thus, combination therapies of two or more
chemotherapeutic agents are an increasingly important strat-
egy for achieving more complete anticancer effects based on
synergistic efficacy [21,22]. Co-therapy of many chemothera-
peutics, such as doxorubicin, PTX, gemcitabine, erlotinib,
5-fluorouracil, and carboplatin, has been used to treat many
difficult-to-cure cancers.
We have developed a series of albumin-based nanoparticles
including PTX, doxorubicin, tacrolimus, or TNF-related apop-
tosis inducing ligand (TRAIL) [3,4,23]. Herein, we prepared and
characterized paclitaxel and curcumin co-bound albumin
nanoparticles (PTX/CCMAlb-NPs) for use in cancer therapy.The
relevant NPs were prepared via high-pressure homogeniza-
tion followed by rotary evaporation.The basic physicochemical
properties and penetration of pancreatic Mia Paca-2 cells by
these PTX/CCM Alb-NPs were carefully investigated.
2. Materials and methods
2.1. Materials
PTX was obtained from JW Pharmaceutical (Dangjin, South
Korea). CCM and bovine serum albumin (BSA) were pur-
chased from Sigma-Aldrich (St. Louis,MO, USA). In situ cell death
detection kits were obtained from BD Pharmingen (Heidel-
berg, Germany). All other reagents were obtained from
Sigma-Aldrich.
2.2. Preparation of PTX/CCM Alb-NPs
PTX or CCMAlb-NPs and PTX/CCMAlb-NPs were prepared using
a slight modification of the NabTM technology. Briefly, 10mg PTX,
4 mg CCM or 5 mg PTX/2 mg CCM were dissolved individu-
ally in 200 μl of a 9:1 solution of chloroform:ethanol. BSA
(100 mg) was dissolved in 10 ml deionized water (DW). The
organic and aqueous phase solutions were gently mixed to-
gether, and the emulsion was high-pressure homogenized with
nine cycles at 20,000 psi using an EmulsiFlex-B15 device
(Avestin, Ottawa, ONT, Canada). The resulting dispersion was
rotary evaporated to remove chloroform at 40 °C for 15 min
under reduced pressure. The NPs were gently centrifuged at
6000 rpm, and the supernatant was lyophilized and stored at
−20 °C until required.
2.3. Characterization of PTX/CCM Alb-NPs
The particle sizes and zeta potential of the PTX/CCM Alb-NPs
were measured using a Zetasizer Nano-ZS90 (Malvern Instru-
ments, Malvern, UK) and a 633 nm He-Ne laser beam at a fixed
scattering angle of 90°. Experiments were performed at an NP
concentration of 1 mg/ml on a BSA weight basis, with the Alb-
NPs dispersed in DW tomeasure the zeta potential.The surface
morphologies of the Alb-NPs were observed using field-
emission scanning electron microscopy (FE-SEM) using a LEO
SUPRA 55 microscope (Carl Zeiss, Jena, Germany) and by trans-
mission electron microscopy (TEM) with a model H-7600
microscope (Hitachi, Tokyo, Japan).
2.4. Cytotoxicity and cellular uptake assessments for
PTX/CCM Alb-NPs
Mia Paca-2 human pancreatic carcinoma cells (Korea Cell Line
Bank, Seoul, Korea) were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM; Gibco, Carlsbad, CA, USA) containing 10% (v/v)
fetal bovine serum (Gibco) and 1% penicillin/streptomycin
(Gibco) in a 5% CO2, 95% relative humidity incubator at 37 °C
as described previously. To examine the cytotoxicity of PTX
Alb-NPs or PTX/CCM Alb-NPs, the cells were seeded in 96-
well plates at 1 × 104 cells/well and pre-incubated for 24 h.Media
were discarded and 1% FBS DMEM containing pre-determined
amounts of the respective samples was added, and the cells
were incubated for 48 h. The cytotoxicity of PTX/CCM Alb-
NPs was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-based assay, and inhibitory
concentrations (IC50) were calculated. Nuclei were labeled with
DAPI blue fluorescent dye (Sigma-Aldrich), according to the
manufacturer’s protocol, to detect intracellular uptake of PTX/
CCM Alb-NPs.The excitation/emission wavelengths were 340/
488 nm for DAPI and 420/529 nm for the PTX/CCM Alb-NPs.
Fluorescence images were analyzed using a confocal laser scan-
ning microscopy (CLSM) Image Browser software (Carl Zeiss).
2.5. Loading efficiency and release of PTX and CCM
To determine the loading efficiency of PTX, a 1 mg portion of
lyophilized PTX/CCM Alb-NPs was mixed with 0.4 ml of a 1:1
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solution of acetonitrile (ACN) and DW and thoroughly shaken
for 5min.The supernatant was subjected to reverse-phase high-
performance liquid chromatography (RP-HPLC) using a PLRP-S
Zorbax 100 RP-18 column (150mm × 4.6 mm, 8 μm/300Å; Agilent
Technologies, Palo Alto, CA, USA) at ambient temperature. A
combined gradient plus isocratic elution method was carried
out at a flow-rate of 1.0 ml/min using solvent A (DW contain-
ing 0.1% trifluoroacetic acid) and solvent B (ACN containing 0.1%
trifluoroacetic acid); that is, 0–70% B for 8 min, 70% B for 10 min,
and 100% A for 4 min. Eluates were monitored at 230 nm. Drug
loading efficiency (%) was calculated as [quantity of drug
entrapped/quantity of drug loaded] × 100.
To investigate PTX and CCM release profiles, 20 mg PTX/
CCM Alb-NPs was suspended in 2 ml 10 mM PBS and dialyzed
using a semipermeable membrane with amolecular weight cut-
off of 10 kDa (Spectrum Labs, Rancho Dominguez, CA, USA)
against 1 l of the same buffer solution at 37 °C. A 0.1 ml aliquot
of sample was withdrawn from the dialysis bag at 3, 6, 9, 12,
15, 18, and 24 h during the incubation. PTX and CCM concen-
trations were determined in the PTX/CCMAlb-NPs as described
above. Cumulative release is expressed as percentage vs. initial
loading amount at each time point. All samples were pre-
pared and analyzed in triplicate (n = 3).
2.6. Stability of PTX/CCM Alb-NPs
Particle size of the PTX/CCM Alb-NPs was monitored to deter-
mine short-term (1 d) stability. At predetermined times, PTX/
CCM Alb-NP particle size was measured using a Zetasizer
Nano-ZS90.
2.7. Data analysis
Data are presented as mean ± standard deviation. Differ-
ences were detected using Student’s t-test. P-values < 0.05 were
considered significant.
3. Results and discussion
3.1. Preparation and characterization of the PTX/CCM
Alb-NPs
The PTX/CCM Alb-NPs were prepared via the NabTM technol-
ogy that uses high-pressure homogenization (Fig. 1). As shown
in Fig. 1, the RP-HPLC retention times of PTX and CCM were
12.06 and 13.22 min, respectively, and the chromatograms
showed representative sharp peaks for each drug extracted from
the PTX/CCM Alb-NPs (Fig. 2). The particle sizes of the plain
PTX or the plain CCMAlb-NPs and PTX/CCMAlb-NPs were 234.4,
134.9, and 250.4 nm, respectively. However, the zeta poten-
tials of the respective Alb-NPs were similar, and those of plain
PTX or plain CCM Alb-NPs and PTX/CCM Alb-NPs were −31.6,
−31.7, and −29.8 mV, respectively (Fig. 3).
Fig. 1 – Chemical structures of paclitaxel and curcumin and an illustration of paclitaxel/curcumin co-bound albumin
nanoparticles.
Fig. 2 – A representative reversed-phase high performance
liquid chromatogram of paclitaxel and curcumin.
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Naïve PTX and CCM were clearly insoluble as low as 5.6 and
100 μg/ml. As shown in Fig. 4, PTX, CCM, and PTX/CCM drug
powders precipitated or attached to the walls of the glass vials
and even floated. In contrast, their NP formulations were sig-
nificantly dispersed in water without precipitation. Albumin
has many binding sites for hydrophobic chemicals and drugs
or metals [1]; thus, PTX and CCM appeared to be bound. Fur-
thermore, the particle size of the PTX/CCM Alb-NPs was
relatively well maintained after lyophilization and redispersion
(data not shown). Additionally, the PTX and CCM loading ef-
ficiencies of PTX/CCM Alb-NPs were ~96.5% and ~88.6%,
respectively.
Specifically, the fabricated PTX/CCM Alb-NPs were fairly
spherical and had a smooth surface when observed by SEM
and TEM, and their apparent size appeared to be almost the
same with that measured by dynamic light scattering (~250 nm)
(Figs. 5 and 6).
3.2. Stability of the PTX/CCM Alb-NPs
The stability of the PTX/CCM Alb-NPs was evaluated based on
maintaining particle size at ambient temperature for 24 h or
after lyophilization. The particle size of PTX/CCM Alb-NPs de-
creased slightly from 230–250.0 to ~185 nm after the 24 h
incubation (Fig. 7A). This decreased particle size seemed to be
attributable to the gradual release of PTX and CCM. Addition-
ally, the PTX/CCMAlb-NP particle size wasmaintained well after
Fig. 3 – Characterization of paclitaxel/curcumin-bound
albumin-nanoparticles (PTX/CCM Alb-NPs) according to
particle size (A) and zeta potential (B).
Fig. 4 – Photographs showing powder appearance,
solubility, and nanoparticle dispersion of paclitaxel (PTX),
curcumin (CCM), and PTX + CCM.
Fig. 5 – Scanning electron microscopic (SEM) image of
paclitaxel/curcumin albumin-nanoparticles (PTX/CCM Alb-
NPs). Scale bar represents 1 μm.
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lyophilization (average +1.9% increase at initial size of 250 nm
for PTX/CCMAlb-NPs).The powder and colloidal solution forms
of the PTX/CCMAlb-NPs were almost the same as those before
lyophilization (data not shown), indicating that our PTX/CCM
Alb-NPs will be robust when applied to a pharmaceutical
process.
3.3. PTX and CCM release from PTX/CCM Alb-NPs
The PTX/CCMAlb-NP release profile was assessed. PTX release
was slightly faster than CCM release from the PTX/CCM Alb-
NPs (Fig. 7B). Specifically, 97.7 ± 1.7% and 76.2 ± 0.5% of PTX and
CCMwere released from, respectively, over the 1-day test period.
These two drugs appeared to be released independently without
any significant interaction between the two.This 1 d period was
considered sufficient for exhibiting an antitumor effect in vivo
because many studies have shown that intravenously in-
jected Alb-NPs are delivered to tumor sites within 3~12 h via
an enhanced permeability and retention effect [3,4,24].
3.4. CLSM visualization of Mia Paca-2 cellular uptake of
PTX/CCM Alb-NPs
Mia Paca-2 cells treated with PTX/CCMAlb-NPs for 24 h showed
a significant yellow color, whereas those treated with blankAlb-
NPs showed no significant color (Fig. 8), indicating that the PTX/
CCMAlb-NPs were efficiently internalized into Mia Paca-2 cells.
The PTX/CCMAlb-NPs do not have a receptor ligand for tumor
targeting. In general, NPs are efficiently taken up by cancer cells
via endocytosis owing to the only nano-size effect. Further-
more, the 60 kDa glycoprotein (gp60) is highly expressed in
endothelial cells around tumors, and albumin carriers effi-
ciently bind to gp60, forming caveolae of albumin–gp60 complex.
This complex traverses to the tumor interstitium via the so-
called gp60-mediated active transcytosis pathway [2].We expect
that our PTX/CCM Alb-NPs will have great potential to accu-
mulate in tumor sites when applied intravenously.
3.5. Cytotoxicity of PTX Alb-NP or TRAIL/PTX Alb-NPs to
Mia Paca-2 cells
The cytotoxicities of PTX Alb-NPs or PTX/CCM Alb-NPs in Mia
Paca-2 cells were assessed using the MTT assay. Co-treatment
with PTX and CCM using Alb-NPs markedly decreased Mia
Paca-2 cell viability (Fig. 9). The IC50 values of plain PTX Alb-
NPs and PTX/CCMAlb-NPs after a 24 h exposure were 2.86 ± 0.11
and 0.1.49 ± 0.02 ng/ml, respectively. The enhanced cytotoxic-
ity of PTX/CCM Alb-NPs seemed to be due to the combined
treatment of PTX and CCM. Co-treatment of chemotherapeu-
tics has resulted in enhanced antitumor effects in vitro and in
vivo.The combined use of PTX and gemcitabine displays a syn-
ergistic antitumor effect in pancreatic cancer, and tamoxifen
and quercetin co-treatment potentiates the cytotoxic effect to
breast cancer cells. Furthermore, treatment with doxorubi-
cin, 5-fluorouracil, and PTX remarkably enhances the antitumor
effect on liver cancer [25–27]. Similarly, our PTX/CCM Alb-NPs
seemed to be synergistically effective for killing Mia Paca-2 cells
probably via two or more pathways.
Fig. 6 – Transmission electron microscopic (TEM) images of
paclitaxel/curcumin albumin-nanoparticles (PTX/CCM Alb-
NPs). Scale bar represents 50 nm (left) and 0.2 μm (right).
Fig. 7 – In vitro profiles of particle size maintenance stability (A) and cumulative release (B) of PTX/CCM Alb-NPs.
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4. Conclusions
In summary, we developed a PTX/CCM co-bound Alb-NP for-
mulation with a particle size of ~250 nm using high-pressure
homogenization. These NPs were spherically shaped with a
smooth surface and stably maintained their initial particle size
for 24 h. Furthermore, the PTX/CCM Alb-NPs were efficiently
internalized into Mia Paca-2 cells. This system offers the clini-
cal possibility of an improved anti-tumor pharmaceutical to
synergistically suppress pancreatic tumors and may allow
reduced chemotherapeutic doses.
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